Immunotherapy With Nivolumab Improves Lung Cancer Patients’ Survival
News
Results from a clinical trial comparing standard chemotherapy with nivolumab, an immunotherapy drug for the treatment of squamous-non-small cell lung cancer patients, revealed that patients treated with nivolumab lived an average of 3.2 months more than those treated with chemotherapy. ... Read more